ImCheck data at ASCO points to promise for T-cell therapy in AML

French biotech ImCheck Therapeutics is preparing to showcase encouraging interim results for its investigational monoclonal antibody ICT01 at the 2025 ASCO Annual Meeting, highlighting the compound’s potential to improve outcomes in acute myeloid leukemia (AML) patients not eligible for intensive chemotherapy.

The oral presentation will feature updated findings from the Phase I/II EVICTION study evaluating ICT01 in combination with the standard AML regimen of azacitidine and venetoclax (Aza-Ven). According to the abstract, the triple therapy showed a 96% composite complete remission rate, with complete remissions reported in nearly three-quarters of evaluable patients.

Among those who received a 10mg dose of ICT01—now proposed for further development - optimal immune activation was noted. These patients achieved an overall survival rate of 83% at nine months, with the drug also showing activity in patients with adverse genetic mutations such as TP53.